One more takeaway from this interview was the 4th bullet point- 3 cohorts of dose expansion have completed without any DLTs or safety concerns.
I also liked 3 bullet points on the anatomical, molecular and biochemical responses which wraps up the conclusions nicely IMO:![]()
- Forums
- ASX - By Stock
- CU6 - Media and Industry News
One more takeaway from this interview was the 4th bullet point-...
-
- There are more pages in this discussion • 173 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CU6 (ASX) to my watchlist
|
|||||
Last
$7.39 |
Change
0.160(2.21%) |
Mkt cap ! $2.305B |
Open | High | Low | Value | Volume |
$7.00 | $7.44 | $6.96 | $4.961M | 678.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 2734 | $7.39 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$7.41 | 1143 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 2009 | 7.390 |
5 | 3074 | 7.380 |
2 | 1059 | 7.370 |
3 | 1216 | 7.360 |
1 | 950 | 7.350 |
Price($) | Vol. | No. |
---|---|---|
7.410 | 1141 | 15 |
7.420 | 1011 | 4 |
7.430 | 6438 | 9 |
7.440 | 2149 | 5 |
7.450 | 16352 | 6 |
Last trade - 12.02pm 09/09/2024 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |